Mingxing Qian

Mingxing Qian

Auto-generated profile, based on publicly available information

Mingxing Qian


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in EBioMedicine
Verified
Journal Article
Open access
PKPamela Kell
Pamela Kell
RSRohini Sidhu
Rohini Sidhu
MQMingxing Qian
Mingxing Qian
SMSonali Mishra
Sonali Mishra
ENElena-Raluca Nicoli
Elena-Raluca Nicoli
XJXuntian Jiang
Xuntian Jiang
GM1 gangliosidosis is a rare, fatal, neurodegenerative disease caused by mutations in the GLB1 gene and deficiency in β-galactosidase. Delay of symptom onset and increase in lifespan in a GM1 gangliosidosis cat model after adeno-associated viral (AAV) gene therapy treatment provide the basis for AAV gene therapy trials. The availability of validated biomarkers would greatly improve assessment of therapeutic efficacy. The liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to screen oligosaccharides as potential biomarkers for GM1 gangliosidosis. The structures of pentasaccharide biomarkers were determined with mass spectrometry, as well as chemical and enzymatic degradations. Comparison of LC-MS/MS data of endogenous and synthetic compounds confirmed the identification. The study samples were analyzed with fully validated LC-MS/MS methods. We identified two pentasaccharide biomarkers, H3N2a and H3N2b, that were elevated more than 18-fold in patient plasma, cerebrospinal fluid (CSF), and urine. Only H3N2b was detectable in the cat model, and it was negatively correlated with β-galactosidase activity. Following intravenous (IV) AAV9 gene therapy treatment, reduction of H3N2b was observed in central nervous system, urine, plasma, and CSF samples from the cat model and in urine, plasma, and CSF samples from a patient. Reduction of H3N2b accurately reflected normalization of neuropathology in the cat model and improvement of clinical outcomes in the patient. These results demonstrate that H3N2b is a useful pharmacodynamic biomarker to evaluate the efficacy of gene therapy for GM1 gangliosidosis. H3N2b will facilitate the translation of gene therapy from animal models to patients. This work was supported by grants U01NS114156, R01HD060576, ZIAHG200409, and P30 DK020579 from the National Institutes of Health (NIH) and a grant from National Tay-Sachs and Allied Diseases Association Inc.

31 December 2024 in Journal of Lipid Research
Verified
Journal Article
Open access
LDLaura Depta
Laura Depta
HBHogan P. Bryce-Rogers
Hogan P. Bryce-Rogers
NDNienke J. Dekker
Nienke J. Dekker
ABAnna Wiehl Bønke
Anna Wiehl Bønke
NCNicolò Camporese
Nicolò Camporese
LLLuca Laraia
Luca Laraia
Sterol transport proteins (STPs) play a pivotal role in cholesterol homeostasis and therefore are essential for healthy human physiology. Despite recent advances in dissecting functions of STPs in the human cell, there is still a significant knowledge gap regarding their specific biological functions and a lack of suitable selective probes for their study. Here, we profile fluorescent steroid-based probes across ten STPs, uncovering substantial differences in their selectivity, aiding the retrospective and prospective interpretation of biological results generated with those probes. These results guided the establishment of an STP screening panel combining diverse biophysical assays, enabling the evaluation of 42 steroid-based natural products and derivatives. Combining this with a thorough structural analysis revealed the molecular basis for STP-specific selectivity profiles, leading to the uncovering of several new potent and selective Aster-B inhibitors and supporting the role of this protein in steroidogenesis.

11 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
QNQingwei Niu
Qingwei Niu
SVSimon Vu
Simon Vu
YXYuanjiang Xu
Yuanjiang Xu
MQMingxing Qian
Mingxing Qian
ARAnastasiia Rudenko
Anastasiia Rudenko
PLPolina V. Lishko
Polina V. Lishko
The inwardly rectifying potassium channel Kir7.1 is essential for the physiological function of diverse tissues, including the retinal pigment epithelium and the gestational myometrium. Loss-of-function mutations in KCNJ13 , which encodes Kir7.1, or conditional ablation of Kir7.1 in the retinal pigment epithelium, lead to early-onset vision loss. Despite strong genetic evidence supporting Kir7.1 as a therapeutic target, its regulation by endogenous ligands—beyond phosphoinositides—remains poorly understood. Here, we report cryo-electron microscopy structures of human Kir7.1 in multiple functional states at resolutions ranging from 2.8 Å to 4.0 Å. These structures uncover the molecular basis of Kir7.1 modulation by PI 4,5 P 2 , its selectivity, rectification, and identify a distinct steroid-binding site that may mediate cooperative channel gating. Our data suggest that endogenous cholesterol acts as an inhibitory ligand, which is displaced by select activating steroids. These activating steroids work in concert with PI 4,5 P 2 to promote channel opening through profound changes in cytoplasmic domains, and the linker region. Electrophysiological analyses define a pharmacological landscape of Kir7.1 activators, providing innovative tools to probe and modulate channel function in both physiological and pathological contexts.

16 August 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
BVBenjamin Volvovitz
Benjamin Volvovitz
Rakib MiahRakib Miah
Rakib Miah
KPKi-beom Park
Ki-beom Park
JKJae Hun Kim
Jae Hun Kim
RVRaul Satoshi Vargas
Raul Satoshi Vargas
VJVesna Jevtovic-Todorovic
Vesna Jevtovic-Todorovic
Although opioids are effective in treating pain, they cause serious side effects. The use of regional anesthesia, although effective in the perioperative period, may not be suitable if mobility and lack of numbness is desired. Hence, there is a clear need for novel pain therapies. Low-voltage activated (T-type) calcium channels (CaV3.2 isoform) could be a promising therapeutic target for the development of novel pain therapies. Indeed, our published findings suggest that novel neuroactive steroid (NAS) analogs that modulate the activity of CaV3.2 channels have unique anti-nociceptive properties. However, the concern with current NASs appears to be their hypnotic/sedative properties, thus potentially hindering the future development of NASs for novel pain therapies. Hence, we developed a new line of NASs that are effective blockers of neuronal CaV3.2 channels in pain pathways while having more favorable pharmacodynamic properties, i.e., lack of sedative/hypnotic side effects. We present two promising novel analogs of NASs—B372 ((3β,5α,17β)-3-Hydroxyandrostan-17-carbonitrile) and YX23 ((3β,5α,17β)-3-Methoxyestran-17-ol). Using an in vitro approach, we show that B372 and YX23 are effective in blocking CaV3.2 channels. Using an in vivo approach, we show that they are effective anti-nociceptives in wild-type but not CaV3.2 knock-out mice. Importantly, we show that they lack sedative/hypnotic effects.

21 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
OMOfer Moldavski
Ofer Moldavski
PZPeter-James H. Zushin
Peter-James H. Zushin
CBCharles A. Berdan
Charles A. Berdan
RERobert J. Van Eijkeren
Robert J. Van Eijkeren
XJXuntian Jiang
Xuntian Jiang
RZRoberto Zoncu
Roberto Zoncu
Oxysterols are oxidized derivatives of cholesterol that play signaling roles in lipid biosynthesis and homeostasis. Here we show that 4β-hydroxycholesterol (4β-HC), a liver and serum abundant oxysterol of poorly defined function, is a potent and selective inducer of the master lipogenic transcription factor, Sterol Regulatory Element Binding Protein 1c (SREBP1c), but not the related steroidogenic transcription factor SREBP2. Mechanistically, 4β-HC acts as a putative agonist for Liver X receptor (LXR), a sterol sensor and transcriptional regulator previously linked to SREBP1c activation. Unique among the oxysterol agonists of LXR, 4β-HC induced expression of the lipogenic program downstream of SREBP1c, and triggered de novo lipogenesis both in primary hepatocytes and in mouse liver. 4β-HC-acted in parallel to insulin-PI3K-dependent signaling to stimulate triglyceride synthesis and lipid droplet accumulation. Thus, 4β-HC is an endogenous regulator of de novo lipogenesis through the LXR-SREBP1c axis.

22 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LDLaura Depta
Laura Depta
HBHogan P. Bryce-Rogers
Hogan P. Bryce-Rogers
NDNienke J. Dekker
Nienke J. Dekker
ABAnna Wiehl Bønke
Anna Wiehl Bønke
NCNicolo’ Camporese
Nicolo’ Camporese
LLLuca Laraia
Luca Laraia
Sterol transport proteins (STPs) play a pivotal role in cholesterol homeostasis and therefore are essential for healthy human physiology. Despite recent advances in dissecting functions of STPs in the human cell, there is still a significant knowledge gap regarding their specific biological functions and a lack of suitable selective probes for their study. Here, we profile fluorescent steroid-based probes across ten STPs, uncovering substantial differences in their selectivity, aiding the retrospective and prospective interpretation of biological results generated with those probes. These results guided the establishment of an STP screening panel combining diverse biophysical assays, enabling the evaluation of 41 steroid-based natural products and derivatives. Combining this with a thorough structural analysis revealed the molecular basis for STP specific selectivity profiles, leading to the uncovering of several new potent and selective Aster-B inhibitors, and supporting the role of this protein in steroidogenesis.